8-K: Caribou Biosciences Reports Strong Q3 2025 & Clinical Milestones

Caribou Biosciences announced positive clinical data for its CAR-T cell therapies vispa-cel and CB-011, alongside its third quarter 2025 financial results.

Summary

• Caribou Biosciences reported positive clinical data from its ANTLER phase 1 trial for vispa-cel (CB-010) in second-line large B cell lymphoma (2L LBCL), demonstrating efficacy and durability on par with autologous CAR-T cell therapies and a safety profile allowing for outpatient use.
• The company also announced positive first clinical data from the CaMMouflage phase 1 trial for CB-011 in relapsed or refractory multiple myeloma (r/r MM), showing deep, durable responses and manageable safety.
• For the third quarter ended September 30, 2025, licensing and collaboration revenue was $2.2 million, up from $2.0 million in Q3 2024.
• Research and development expenses decreased to $22.4 million in Q3 2025 from $30.4 million in Q3 2024, primarily due to a reduction in workforce and strategic pipeline prioritization.
• General and administrative expenses decreased to $9.2 million in Q3 2025 from $9.8 million in Q3 2024, also related to workforce reduction.
• Net loss for Q3 2025 was $27.548 million, an improvement from a net loss of $34.684 million in Q3 2024.
• Caribou held $159.2 million in cash, cash equivalents, and marketable securities as of September 30, 2025, down from $249.4 million as of December 31, 2024.
• The company expects its current cash to fund operations into the second half of 2027, covering CB-011 dose expansion and initial activities for the planned vispa-cel pivotal trial.
• Caribou is exploring multiple options to fully fund its planned vispa-cel pivotal trial.

Sentiment

Score: 8

Explanation: The company reported strong positive clinical trial results for both its lead CAR-T cell therapy candidates, vispa-cel and CB-011, demonstrating efficacy and safety profiles that position them as potential best-in-class allogeneic therapies. Financial results showed reduced operating expenses and an extended cash runway, although a future capital raise is anticipated to fully fund a pivotal trial.

Positives

• Vispa-cel ANTLER phase 1 trial data in the confirmatory cohort (N=22) showed an 82% overall response rate (ORR), 64% complete response (CR) rate, and 51% progression-free survival (PFS) at 12 months.
• Vispa-cel data for the optimized profile cohort (N=35) demonstrated an 86% ORR, 63% CR rate, and 53% PFS at 12 months.
• Vispa-cel's generally well-tolerated safety profile allows for administration in the outpatient setting and at community hospitals.
• The longest responding vispa-cel patient is in complete response 3 years post infusion.
• CB-011 CaMMouflage phase 1 trial data at the recommended dose for expansion (RDE) in BCMA-naive patients (N=12) showed a 92% ORR, 75% CR, and 91% minimal residual disease (MRD)-negativity.
• Research and development expenses decreased by $8.0 million in Q3 2025 compared to Q3 2024.
• General and administrative expenses decreased by $0.6 million in Q3 2025 compared to Q3 2024.
• Cash, cash equivalents, and marketable securities are expected to fund operations into 2H 2027.

Negatives

• Net loss for the nine months ended September 30, 2025, was $121.637 million, an increase from $113.615 million for the same period in 2024.
• Cash, cash equivalents, and marketable securities decreased by $90.2 million from $249.4 million as of December 31, 2024, to $159.2 million as of September 30, 2025.
• The company is exploring multiple options to fully fund its planned vispa-cel pivotal trial, indicating a future need for capital.

Risks

• Risks inherent in the development of allogeneic CAR-T cell therapy products.
• Uncertainties related to the initiation, cost, timing, progress, and results of current and future clinical trials.
• The risk that initial, preliminary, or interim clinical trial data will not ultimately be predictive of the safety and efficacy of product candidates or that clinical outcomes may differ as patient enrollment continues and more patient data becomes available.
• The risk that different conclusions or considerations are reached once additional data have been received and fully evaluated.
• The ability to obtain key regulatory input and approvals.
• Risks related to the company's limited operating history, history of net operating losses, financial position, and its ability to raise additional capital as needed to fund operations and product candidate development, including fully funding the pivotal phase 3 clinical trial for vispa-cel.
• Caution should be exercised when interpreting results from separate trials involving commercially approved autologous CAR-T cell therapies, as cross-trial comparisons may have no interpretive value due to material differences in trial design, patient population, and other important factors.

Future Outlook

Caribou Biosciences intends to follow the FDA's recommendation to conduct a randomized, controlled pivotal phase 3 clinical trial for vispa-cel in 2L LBCL CD19-naive patients who are ineligible for transplant and autologous CAR-T cell therapy, with further refinement of the trial design through continued engagement with the FDA. The company plans to advance CB-011 into dose expansion by the end of 2025 and expects to report dose expansion data, along with longer follow-up on dose escalation data, in 2026. Caribou anticipates its current cash, cash equivalents, and marketable securities will be sufficient to fund its operating plan, including CB-011 dose expansion and certain start-up activities for the vispa-cel pivotal trial, into the second half of 2027. The company is actively exploring multiple options to fully fund the planned vispa-cel pivotal trial.

Management Comments

• "We were thrilled to recently share positive clinical data from both our off-the-shelf CAR-T cell therapy programs, vispa-cel for second-line large B cell lymphoma and CB-011 for relapsed or refractory multiple myeloma. These results represent a defining moment for our company and the field of allogeneic CAR-T cell therapy." Rachel Haurwitz, PhD, President and CEO.
• "As we advance both programs, we are committed to delivering on the promise of off-the-shelf cell therapies — offering rapid treatment, scalable manufacturing, and the possibility of broad patient access." Rachel Haurwitz, PhD, President and CEO.

Industry Context

The positive clinical data for Caribou's allogeneic CAR-T cell therapies, vispa-cel and CB-011, position the company as a significant player in the rapidly evolving cell therapy landscape. The 'off-the-shelf' nature of these therapies addresses key limitations of autologous CAR-T treatments, such as manufacturing time and patient access. Vispa-cel's demonstrated efficacy on par with autologous therapies and its safety profile allowing for outpatient administration could be a transformative development for lymphoma treatment, potentially expanding CAR-T therapy access to community settings. Similarly, CB-011's deep and durable responses in multiple myeloma highlight its potential to compete in a challenging indication. These advancements could accelerate the shift towards more accessible and scalable cell therapy options, impacting the broader oncology market.

Comparison to Industry Standards

• Vispa-cel (CB-010) ANTLER phase 1 data demonstrated efficacy and durability described as "on par with autologous CAR-T cell therapies" for large B cell lymphoma (LBCL).
• Vispa-cel's generally well-tolerated safety profile is highlighted as allowing for administration in the outpatient setting and at community hospitals, which could offer a significant logistical advantage compared to many existing autologous CAR-T therapies.
• CB-011 CaMMouflage phase 1 data demonstrated deep, durable responses and manageable safety, positioning it as a potential "best-in-class allogeneic CAR-T cell therapy" for relapsed or refractory multiple myeloma (r/r MM).
• The company explicitly cautions that results from separate trials involving commercially approved autologous CAR-T cell therapies may not be comparable to Caribou's clinical results due to material differences in trial design, patient population, and other factors.

Stakeholder Impact

• Shareholders: Positive clinical data and extended cash runway could increase investor confidence, but potential future dilution from a capital raise to fund the pivotal trial is noted.
• Patients: The development of off-the-shelf CAR-T cell therapies with comparable efficacy to autologous treatments and the potential for outpatient administration could significantly improve access and treatment options for patients with LBCL and r/r MM.
• Employees: Recent reduction in workforce and strategic pipeline prioritization indicates restructuring, which may have impacted some employees.
• Regulatory Authorities: Ongoing engagement with the FDA is crucial for the design and progression of the vispa-cel pivotal trial.

Next Steps

• Refine the planned pivotal phase 3 clinical trial design for vispa-cel through continued engagement with the FDA.
• Advance CB-011 into dose expansion by the end of 2025.
• Report CB-011 dose expansion data and longer follow-up on dose escalation data in 2026.
• Attend the 8th Annual Evercore Healthcare Conference on December 2, 2025, for a fireside chat.
• Host a breakfast reception and KOL panel at the 67th ASH Annual Meeting on December 6, 2025.
• Explore multiple options to fully fund the planned vispa-cel pivotal trial.

Key Dates

Recommendation

The company has delivered highly compelling clinical data for both its lead allogeneic CAR-T programs, vispa-cel and CB-011, demonstrating efficacy and safety profiles that are competitive with, and in some aspects superior to, existing autologous therapies. The ability to administer vispa-cel in an outpatient setting represents a significant market advantage and addresses a key bottleneck in CAR-T delivery. While a future capital raise is indicated, the strong clinical validation significantly de-risks the investment thesis and positions Caribou as a leader in the next generation of cell therapies. The extended cash runway provides sufficient time to advance these programs and secure funding on favorable terms.

Keywords

CRISPR, CAR-T cell therapy, allogeneic, vispa-cel, CB-011, large B cell lymphoma, multiple myeloma, clinical trial, biopharmaceutical, genome-editing, oncology, hematologic malignancies